Zhou Q, Wang Y, Si G, Chen X, Mu D, Zhang B
Chem Biomed Imaging. 2025; 3(2):51-76.
PMID: 40018650
PMC: 11863161.
DOI: 10.1021/cbmi.4c00064.
Wang L, Tian G
Transl Cancer Res. 2025; 13(12):7015-7025.
PMID: 39816548
PMC: 11730190.
DOI: 10.21037/tcr-2024-2436.
Zhou X, Wang H, Yan B, Nie X, Chen Q, Yang X
Cardiovasc Drugs Ther. 2024; .
PMID: 39641901
DOI: 10.1007/s10557-024-07642-5.
Nishimura A, Tanaka T, Shimoda K, Ida T, Sasaki S, Umezawa K
Redox Biol. 2024; 79():103445.
PMID: 39637599
PMC: 11663985.
DOI: 10.1016/j.redox.2024.103445.
Zhu B, Liao Q, Tian H, Yu D, Xie T, Sun X
Front Pharmacol. 2024; 15:1478819.
PMID: 39575382
PMC: 11578702.
DOI: 10.3389/fphar.2024.1478819.
Improving understanding of ferroptosis: Molecular mechanisms, connection with cellular senescence and implications for aging.
De Leon-Oliva D, Boaru D, Minaya-Bravo A, De Castro-Martinez P, Fraile-Martinez O, Garcia-Montero C
Heliyon. 2024; 10(21):e39684.
PMID: 39553553
PMC: 11564042.
DOI: 10.1016/j.heliyon.2024.e39684.
Inhibition of VDAC1 oligomerization blocks cysteine deprivation-induced ferroptosis via mitochondrial ROS suppression.
Jang S, Ahn S, Kim G, Kim S, Hong J, Park K
Cell Death Dis. 2024; 15(11):811.
PMID: 39521767
PMC: 11550314.
DOI: 10.1038/s41419-024-07216-1.
The mechanism and therapeutic strategies in doxorubicin-induced cardiotoxicity: Role of programmed cell death.
Li Y, Yan J, Yang P
Cell Stress Chaperones. 2024; 29(5):666-680.
PMID: 39343295
PMC: 11490929.
DOI: 10.1016/j.cstres.2024.09.001.
Induction of Non-Canonical Ferroptosis by Targeting Clusters Suppresses Glioblastoma.
Cao K, Xue L, Luo K, Huo W, Ruan P, Xia D
Pharmaceutics. 2024; 16(9).
PMID: 39339241
PMC: 11434859.
DOI: 10.3390/pharmaceutics16091205.
Ultrasound targeted microbubble destruction assisted exosomal delivery of siHmox1 effectively inhibits doxorubicin-induced cardiomyocyte ferroptosis.
Chen J, Qiu S, Liu Y, Sun W, Zhou T, Zhao L
J Nanobiotechnology. 2024; 22(1):531.
PMID: 39218878
PMC: 11367924.
DOI: 10.1186/s12951-024-02794-w.
Sarmentosin alleviates doxorubicin-induced cardiotoxicity and ferroptosis the p62-Keap1-Nrf2 pathway.
Lin Z, Wu C, Song D, Zhu C, Wu B, Wang J
Redox Rep. 2024; 29(1):2392329.
PMID: 39150892
PMC: 11332294.
DOI: 10.1080/13510002.2024.2392329.
Ferroptosis as an emerging target in sickle cell disease.
Fortuna V, Lima J, Oliveira G, Oliveira Y, Getachew B, Nekhai S
Curr Res Toxicol. 2024; 7:100181.
PMID: 39021403
PMC: 11252799.
DOI: 10.1016/j.crtox.2024.100181.
Protosappanin A Protects DOX-Induced Myocardial Injury and Cardiac Dysfunction by Targeting ACSL4/FTH1 Axis-Dependent Ferroptosis.
Cui J, Chen Y, Yang Q, Zhao P, Yang M, Wang X
Adv Sci (Weinh). 2024; 11(34):e2310227.
PMID: 38984448
PMC: 11425893.
DOI: 10.1002/advs.202310227.
The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.
Kontoghiorghes G
Int J Mol Sci. 2024; 25(9).
PMID: 38731873
PMC: 11083551.
DOI: 10.3390/ijms25094654.
Therapeutic Effects of Melatonin in the Regulation of Ferroptosis: A Review of Current Evidence.
Pourhanifeh M, Hosseinzadeh A, Koosha F, Reiter R, Mehrzadi S
Curr Drug Targets. 2024; 25(8):543-557.
PMID: 38706348
DOI: 10.2174/0113894501284110240426074746.
Editorial Commentary: Copper Homeostasis in Neurodegenerative Diseases.
Li Y, Wang K
Curr Med Sci. 2024; 44(1):244-245.
PMID: 38393531
DOI: 10.1007/s11596-024-2841-y.
Ferroptosis Exists in Ischemia Reperfusion Injury after Cardiac Surgery with Cardiopulmonary Bypass.
Zhang S, Li J, Wang J, Chen X, Shu G, Feng D
Cell Biochem Biophys. 2024; 82(2):777-786.
PMID: 38363517
DOI: 10.1007/s12013-024-01228-6.
Targeting ferroptosis and ferritinophagy: new targets for cardiovascular diseases.
Luan Y, Yang Y, Luan Y, Liu H, Xing H, Pei J
J Zhejiang Univ Sci B. 2024; 25(1):1-22.
PMID: 38163663
PMC: 10758208.
DOI: 10.1631/jzus.B2300097.
Ferroptosis: Emerging Role in Diseases and Potential Implication of Bioactive Compounds.
Patane G, Putaggio S, Tellone E, Barreca D, Ficarra S, Maffei C
Int J Mol Sci. 2023; 24(24).
PMID: 38139106
PMC: 10744228.
DOI: 10.3390/ijms242417279.
Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs.
Kontoghiorghes G
Int J Mol Sci. 2023; 24(23).
PMID: 38069073
PMC: 10706143.
DOI: 10.3390/ijms242316749.